BTIG analyst Mark Massaro has initiated coverage on Tempus AI (TEM), with a Buy rating and a price target of $60, implying 48 ...

Tempus AI has reported impressive growth, but some of the volatile quarterly numbers have chased off aggressive investors.

We recently published a list of Top 10 AI Stocks Making Headlines Today In this article, we are going to take a look at where ...

Despite recent volatility, Tempus' AI-driven healthcare strategy and expansion plans draw a bullish call from BTIG ...

Tempus AI reports 30.4% YoY revenue growth in FY2024, driven by genomics and data services. Discover key metrics and ...

Fintel reports that on April 21, 2025, BTIG initiated coverage of Tempus AI (NasdaqGS:TEM) with a Buy recommendation. Analyst ...

As previously reported, BTIG initiated coverage of Tempus AI (TEM) with a Buy rating and $60 price target Tempus AI is a rapidly growing ...

Tempus AI has launched an advisory board of oncology experts to provide guidance and strategic advice to the Chicago-based company on research, product development and clinical use of it's AI-enabled ...

Tempus AI, Inc. has a 12 month low of $22.89 and a 12 month high of $91.45. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Illumina & Tempus collaborate to drive future of precision medicine through genomic AI innovation: San Diego Saturday, April 19, 2025, 12:00 Hrs [IST] Illumina Inc. and Tempus AI, ...